A detailed history of New York State Common Retirement Fund transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 20,902 shares of COGT stock, worth $186,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,902
Previous 29,902 30.1%
Holding current value
$186,027
Previous $252,000 10.32%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$8.24 - $11.48 $74,160 - $103,320
-9,000 Reduced 30.1%
20,902 $226,000
Q2 2024

Jul 31, 2024

SELL
$6.01 - $9.04 $24,154 - $36,331
-4,019 Reduced 11.85%
29,902 $252,000
Q1 2024

May 07, 2024

BUY
$4.38 - $9.02 $58,516 - $120,507
13,360 Added 64.98%
33,921 $228,000
Q4 2023

Feb 01, 2024

SELL
$4.06 - $10.08 $50,315 - $124,921
-12,393 Reduced 37.61%
20,561 $121,000
Q3 2023

Nov 07, 2023

BUY
$9.69 - $13.34 $104,361 - $143,671
10,770 Added 48.55%
32,954 $321,000
Q2 2023

Aug 07, 2023

SELL
$9.85 - $13.24 $93,131 - $125,184
-9,455 Reduced 29.88%
22,184 $263,000
Q1 2023

May 02, 2023

SELL
$10.04 - $15.5 $144,837 - $223,603
-14,426 Reduced 31.32%
31,639 $341,000
Q4 2022

Jan 30, 2023

BUY
$10.65 - $14.84 $41,992 - $58,514
3,943 Added 9.36%
46,065 $533,000
Q3 2022

Nov 08, 2022

BUY
$9.39 - $16.99 $156,503 - $283,172
16,667 Added 65.48%
42,122 $628,000
Q2 2022

Aug 04, 2022

SELL
$3.92 - $9.73 $352 - $875
-90 Reduced 0.35%
25,455 $230,000
Q1 2022

May 05, 2022

BUY
$5.31 - $8.7 $207 - $339
39 Added 0.15%
25,545 $191,000
Q4 2021

Feb 02, 2022

SELL
$7.51 - $10.81 $593 - $853
-79 Reduced 0.31%
25,506 $219,000
Q3 2021

Nov 02, 2021

SELL
$5.99 - $9.14 $37,227 - $56,805
-6,215 Reduced 19.54%
25,585 $215,000
Q2 2021

Aug 02, 2021

BUY
$7.82 - $9.3 $248,676 - $295,740
31,800 New
31,800 $258,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $585M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.